MEDIA RELEASE PR35825
SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese
Pharmaceutical Company
AMSTERDAM, Sep. 1 /PRNewswire-AsiaNet/ --
SynCo Bio Partners B.V., the expert in long term GMP contract
manufacturing of biopharmaceuticals announced today that it has expanded its
business into a new geographical market, with the signing of a contract to
manufacture a live biotherapeutic for an emerging Japanese pharmaceutical
company.
The undisclosed company's product is an innovative live
biotherapeutic based anticancer drug. The project will first involve a
consultancy phase, during which SynCo will assist the client with in-house
process development. The developed process will then be transferred to
SynCo's Amsterdam facility and scaled-up, prior to GMP manufacture for Phase
I clinical trials, including fermentation, formulation and aseptic filling.
"We are extremely pleased to be working with our first Japanese
partner," commented SynCo's CEO, Mr. Pierre Warffemius, "this is an exciting
project for a leading Japanese business and I look forward to the successful
completion of GMP manufacture, in the field of live biotherapeutics. This
contract represents SynCo's entry into the growing Japanese biotherapeutics
market and is reflective of our continuing success in a very competitive GMP
contract manufacturing market."
SynCo is a specialist in the development of manufacturing
processes and GMP production of live biotherapeutics and provides a
one-stop-shop for the production of both bulk drug substance and final
lyophilized product. This project is one of a rapidly growing number SynCo is
involved with in this field.
About SynCo Bio Partners B.V.
SynCo Bio Partners is a GMP-licensed bulk drug substance and
final product CMO with clinical and commercial production experience with
mammalian and microbial systems. This experience has been acquired by
developing new production processes for a number of international clients and
producing a wide variety of different vaccines, live bacterial products and
recombinant proteins in our state-of-the-art, GMP-licensed facilities since
inception in 2000.
Focused solely on biopharmaceuticals, SynCo Bio Partners acts
as a strategic, long-term partner delivering product on time to the highest
quality standards. SynCo 's team are committed to exceeding customer
expectations taking a truly collaborative approach to manufacturing.
SOURCE: SynCo Bio Partners B.V.
Translations:
NEWS 
